Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: A cross-sectional, observational pilot study

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 757, Issue 1, 2013, Pages 31-35

  Oz Gul, Ozen ^a   Cinkilic, Nilufer ^a   Gul, Cuma Bulent ^a   Cander, Soner ^a   Vatan, Ozgur ^a   Ersoy, Canan ^a   Yılmaz, Dilek ^a   Tuncel, Ercan ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Cytotoxicity; Genotoxicity; Pioglitazone; Rosiglitazone; Sitagliptin; Type 2 diabetes

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; CELLULAR PARAMETERS; CHROMOSOME ABERRATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOTOXICITY; FEMALE; GENOTOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICRONUCLEUS; MITOSIS INDEX; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR DIVISION INDEX; OBSERVATIONAL STUDY; PERIPHERAL LYMPHOCYTE; PILOT STUDY; PRIORITY JOURNAL; REPLICATION INDEX; SISTER CHROMATID EXCHANGE; AGED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MIDDLE AGED; PATHOLOGY;

AGED; BLOOD GLUCOSE; CHROMOSOME ABERRATIONS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MIDDLE AGED; PILOT PROJECTS; PYRAZINES; SISTER CHROMATID EXCHANGE; THIAZOLIDINEDIONES; TRIAZOLES;

EID: 84891541369     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2013.04.024     Document Type: Article

References (34)

1. van Dieren, S., Beulens, J.W., van der Schouw, Y.T., Grobbee, D.E., Neal, B., The global burden of diabetes and its complications: an emerging pandemic. Eur. J. Cardiovasc. Prev. Rehabil. 17:Suppl. 1 (2010), S3–S8.
2. Subbarayan, S., Kipnes, M., Sitagliptin: a review. Expert Opin. Pharmacother. 12 (2011), 1613–1622.
3. Dhillon, S., Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 70 (2010), 489–512.
4. Cariou, B., Charbonnel, B., Staels, B., Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol. Metab. 23 (2012), 205–215.
5. Papaetis, G.S., Orphanidou, D., Panagiotou, T.N., Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit. Curr. Drug Targets 12 (2011), 1498–1512.
6. Cho, N., Momose, Y., Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr. Top. Med. Chem. 8 (2008), 1483–1507.
7. Bedir, A., Aliyazicioglu, Y., Kahraman, H., Yurdakul, Z., Uysal, M., Suvaci, D.E., Okuyucu, A., Hökelek, M., Alvur, M., Genotoxicity in rats treated with the antidiabetic agent, rosiglitazone. Environ. Mol. Mutagen. 47 (2006), 718–724.
8. Rachek, L.I., Yuzefovych, L.V., Ledoux, S.P., Julie, N.L., Wilson, G.L., Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol. Appl. Pharmacol. 240 (2009), 348–354.
9. Bedir, A., Aliyazicioglu, Y., Bilgici, B., Yurdakul, Z., Uysal, M., Suvaci, D.E., Okuyucu, A., Kahraman, H., Hökelek, M., Alvur, M., Assessment of genotoxicity in rats treated with the antidiabetic agent, pioglitazone. Environ. Mol. Mutagen. 49 (2008), 185–191.
10. Rabbani, S.I., Devi, K., Khanam, S., Role of pioglitazone with metformin or glimepiride on oxidative stress-induced nuclear damage and reproductive toxicity in diabetic rats, Malays. J. Med. Sci. 17 (2010), 3–11.
11. Alzoubi, K., Khabour, O., Hussain, N., Al-Azzam, S., Mhaidat, N., Evaluation of vitamin B12 effects on DNA damage induced by pioglitazone. Mutat. Res. 748 (2012), 48–51.
12. Shaik, N.A., Shaik, J.P., Ali, S., Imran, A., Rao, D.K., Increased frequency of micronuclei in diabetes mellitus patients using pioglitazone and glimepiride in combination. Food Chem. Toxicol. 48 (2010), 3432–3435.
13. Ishibashi, Y., Matsui, T., Takeuchi, M., Yamagishi, S., Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm. Metab. Res. 43 (2011), 731–734.
14. Rizzo, M.R., Barbieri, M., Marfella, R., Paolisso, G., Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care, 2012, 10.2337/dc12-0199.
15. Elashoff, M., Matveyenko, A.V., Gier, B., Elashoff, R., Butler, P.C., Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141 (2011), 150–156.
16. No authors listed, Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20 (1997), 1183–1197.
17. Oz Gul, O., Tuncel, E., Yilmaz, Y., Ulukaya, E., Gul, C.B., Kiyici, S., Oral, A.Y., Guclu, M., Ersoy, C., Imamoglu, S., Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. Metabolism 59 (2010), 64–69.
18. Carrano, A.V., Natarajan, N.T., International commission for protection against environmental mutagens and carcinogens. ICPEMC publication no. 14. Considerations for population monitoring using cytogenetic techniques. Mutat. Res. 204 (1988), 379–406.
19. IPCS, Guide to Short Term Tests for Detecting Mutagenic and Carcinogenic Chemicals. 1985, World Health Organization, Geneva.
20. Cinkilic, N., Kiyici, S., Celikler, S., Vatan, O., Oz Gul, O., Tuncel, E., Bilaloglu, R., Evaluation of chromosome aberrations, sister chromatid exchange and micronuclei in patients with type-1 diabetes mellitus. Mutat. Res. 676 (2009), 1–4.
21. Fenech, M., Chang, W.P., Kirsch-Volders, M., Holland, N., Bonassi, S., Zeiger, E., HUman MicronNucleus project, HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat. Res. 534 (2003), 65–75.
22. Ivett, J.L., Tice, R.R., Average generation time: a new method of analysis and quantitation of cellular proliferation kinetics. Environ. Mutagen., 4, 1982, 358.
23. Eastmond, D.A., Tucker, J.D., Identification of aneuploidy-inducing agents using cytokinesis-blocked human lymphocytes and an antikinetochore antibody. Environ. Mol. Mutagen. 13 (1989), 34–43.
24. Giovannucci, E., Harlan, D.M., Archer, M.C., Bergenstal, R.M., Gapstur, S.M., Habel, L.A., Pollak, M., Regensteiner, J.G., Yee, D., Diabetes and cancer: a consensus report. Diabetes Care 33 (2010), 1674–1685.
25. Loke, Y.K., Kwok, C.S., Singh, S., Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ, 342, 2011, d1309.
26. Fox, J.T., Sakamuru, S., Huang, R., Teneva, N., Simmons, S.O., Xia, M., Tice, R.R., Austin, C.P., Myung, K., High-throughput genotoxicity assay identifies antioxidants as inducers of DNA damage response and cell death. Proc. Natl. Acad. Sci. U.S.A. 109 (2012), 5423–5428.
27. Ondrey, F., Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin. Cancer Res. 15 (2009), 2–8.
28. Grommes, C., Landreth, G.E., Heneka, M.T., Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 5 (2004), 419–429.
29. Han, S., Roman, J., Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics. Anticancer Drugs 18 (2007), 237–244.
30. Azoulay, L., Yin, H., Filion, K.B., Assayag, J., Majdan, A., Pollak, M.N., Suissa, S., The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case–control study. BMJ, 344, 2012, e3645.
31. Monami, M., Lamanna, C., Marchionni, N., Mannucci, E., Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 31 (2008), 1455–1460.
32. Johnson, J.A., Carstensen, B., Witte, D., Bowker, S.L., Lipscombe, L., Renehan, A.G., Diabetes and cancer research consortium. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55 (2012), 1607–1618.
33. Sun, G., Kashyap, S.R., Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations. J. Nutr. Metab., 2011, 2011, 708183.
34. Monami, M., Dicembrini, I., Martelli, D., Mannucci, E., Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr. Med. Res. Opin. 27:Suppl. 3 (2011), 57–64.